Anixa Secures Australian Patent for Breast Cancer Vaccine, Extending Global IP Through 2040
Event summary
- Anixa Biosciences received Patent Number 2020221280 from IP Australia for its breast cancer vaccine technology, valid through 2040.
- The patent covers a composition-of-matter for the vaccine, exclusively licensed from Cleveland Clinic.
- Phase 1 trial results showed the vaccine was safe, well-tolerated, and generated immune responses in 74% of participants.
- Anixa's global IP portfolio now includes key markets like the U.S., Europe, China, and Japan.
- The vaccine targets human α-lactalbumin, a protein linked to certain types of breast cancer.
The big picture
Anixa's Australian patent strengthens its global IP strategy amid rising breast cancer incidence rates worldwide. The move underscores the company's leadership in cancer immunotherapy, particularly in preventive vaccines—a largely untapped market. With Phase 1 trial success and expanding international protection, Anixa is positioning itself for potential partnerships and commercialization opportunities.
What we're watching
- Regulatory Pathways
- How Anixa will leverage this patent to accelerate regulatory approvals in Australia and other key markets.
- Partnership Potential
- Whether the expanded IP portfolio will attract larger pharmaceutical partners for global commercialization.
- Clinical Development
- The pace at which Anixa advances its breast cancer vaccine through subsequent clinical trials.
Related topics